New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.